News Category
Quantum BioPharma signs a Study Start-Up Agreement with Thermo Fisher's clinical research business to initiate a Phase 2 trial of Lucid-MS, a novel ne...
Regentis Biomaterials is advancing GelrinC, an off-the-shelf hydrogel implant designed to regenerate knee cartilage, with European approval and a U.S....
American Fusion's Texatron fusion program has entered active testing, achieving 100,000 atmospheres of pressure and attracting updated research covera...
The 2026 Disruptive Growth & Life Sciences Conference, organized by Moody Capital Solutions, will connect emerging and under-covered companies with in...
SuzieQ Holdings' participation in the Moody Capital Solutions conference underscores its strategic position in the emerging post-quantum cybersecurity...
A new study confirms that treating certain emergency room patients while seated, rather than waiting for a bed, significantly reduces wait times, pote...
Helus Pharma's Phase 3 program for HLP003 in major depressive disorder is on track with enrollment completed in the first pivotal study, positioning t...
Helus Pharma names Michael Halstead CEO as it advances HLP003 toward Phase 3 data and potential commercialization, signaling strategic leadership for ...
Ocumetics Technology Corp. has completed the second tranche of its private placement, securing $2.5 million to advance its first-in-human clinical tri...
VERAXA Biotech AG shareholders approved key governance and financing changes with over 99.94% support, enabling greater flexibility for growth strateg...
VERAXA Biotech (NASDAQ: VRXA) announced a key technical milestone in its collaboration with OmniAb (NASDAQ: OABI), allowing its bispecific ADC program...
Gerresheimer has opened a new plant in Zhenjiang Dagang, China, doubling its production capacity for glass primary packaging for injectable pharmaceut...
The name change from Darwin AG to Novogenia AG aligns the corporate identity with its core operating brand, enhancing market presence and supporting i...
NanoViricides is progressing its oral gummies formulation of NV-387 toward a Phase II trial for the Bundibugyo ebolavirus outbreak in the DRC, where n...
Redwood AI Corp. was added to the CSE25 Index, reflecting its growth in AI-driven chemistry and drug development, which may attract institutional and ...
Helus Pharma announced fiscal 2026 financial results and provided updates on its clinical pipeline, including Phase 3 progress for HLP003 in major dep...
Quantum BioPharma's potential therapy Lucid-MS, featured in a BioMedWire editorial, aims to directly repair myelin damage in multiple sclerosis, addre...
The article highlights how the $410 billion nanomedicine and advanced drug-delivery market, exemplified by Oncotelic Therapeutics' Deciparticle platfo...
Quantum BioPharma's Lucid-MS, a first-in-class neuroprotective therapy for multiple sclerosis, is preparing for Phase 2 trials after successful Phase ...
VERAXA Biotech announced in vitro data validating its BiTAC-ADC platform, which activates cancer drugs only in tumors, potentially reducing toxicity a...
Redwood AI Corp. is highlighted as a 'One to Watch' for its AI-powered platforms that accelerate chemistry research and development in pharmaceuticals...
NanoViricides announced that the Pillar Committee in Charge in the Democratic Republic of Congo has approved its proposal to conduct a Phase II clinic...
Helus Pharma's participation in a key industry conference highlights its progress in developing novel serotonergic agonists for mental health conditio...
Onco-Innovations Limited has initiated process development and scale-up activities for ONC010, a key step toward IND-enabling studies and first-in-hum...
Quantum BioPharma's LUCID-MS program targets myelin repair in multiple sclerosis, with phase 1 safety data supporting its Investigational New Drug app...
NeuroOne Medical Technologies will present at the Planet MicroCap Las Vegas 2026 Conference on June 17, 2026, providing updates on its OneRF platform ...
GeoVax CEO David Dodd comments on recent pharmaceutical industry transactions signaling a strategic shift toward vaccine innovation, health security, ...
Quantum BioPharma highlights its lead drug candidate Lucid-MS for multiple sclerosis and its commercial alcohol metabolism product unbuzzd(TM), with a...
Helus Pharma's participation in the Jefferies Global Healthcare Conference underscores its advancing clinical programs for depression and anxiety, wit...
TransCode Therapeutics has started a Phase 2a clinical trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, aiming to reduc...
NanoViricides flags its broad-spectrum antiviral NV-387 as a potential treatment for the Bundibugyo Ebola strain, which lacks approved vaccines or the...
SureNano Science Ltd. is advancing GEP-44, a novel GLP-1 peptide for obesity and metabolic disorders, positioning itself in the booming GLP-1 drug mar...
Oncotelic Therapeutics integrates 28 million scientific abstracts into its PDAOAI platform, positioning itself as a leader in the rapidly growing AI-d...
Telomir Pharmaceuticals announced peer-reviewed preclinical data showing Telomir-Zn improved survival and reduced oxidative stress and hepatic copper ...
Lantern Pharma announced FDA support for protocol amendments in its Phase 2 HARMONIC trial evaluating LP-300 in never-smokers with advanced NSCLC, pro...
NanoViricides underscores the potential of its oral drug candidate NV-387 as a pandemic preparedness tool for Ebola and related filoviruses, leveragin...
Quantum BioPharma announced that its collaborative multiple sclerosis imaging study with Massachusetts General Hospital has enrolled half its target p...
LIXTE Biotechnology Holdings announced advancement of its lead candidate LB-100 in ovarian cancer trials and growth at its Liora Technologies subsidia...
Dogwood Therapeutics announced first quarter 2026 financial results, highlighting enrollment progress in its Halneuron Phase 2b CINP study and FDA cle...
Innovative nose-to-brain delivery systems aim to overcome the blood-brain barrier, potentially transforming treatment for neurological diseases and cr...
Silo Pharma announced a strategic initiative to explore ibogaine-based therapeutics for traumatic brain injury and related conditions, filing a provis...
A hantavirus outbreak on the MV Hondius cruise ship has resulted in three deaths, highlighting the dangers of this little-known infection and the impo...
NanoViricides' NV-387 gains FDA Orphan Drug Designation for measles, offering incentives and supporting development against rising global outbreaks.
VolitionRx announced a technical milestone in detecting nucleosomes in capillary blood from sepsis patients using a lateral flow finger-prick prototyp...
Helus Pharma collaborates with TARA Mind and VETS to enhance veteran recruitment for its Phase 3 trial of HLP003, a Breakthrough Therapy-designated tr...
Ventripoint Diagnostics announces that its AI-powered VMS+ 4.0 system has been submitted for NMPA approval in China under an expedited review process,...
Formycon AG announces its fiscal 2025 results on April 22, 2026, with a conference call, and details its participation in international investor confe...
Helus Pharma announced the appointment of Dr. Ken Kramer as SVP of Medical Affairs, bringing over 20 years of neuroscience leadership to support its P...
